In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therapeutics and Galera Therapeutics enter a $350 million merger agreement, and industry leaders explore a new standard for copay program excellence.
Fler avsnitt av Pharmaceutical Executive
Visa alla avsnitt av Pharmaceutical ExecutivePharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
